Cancer treatment reviews最新文献

筛选
英文 中文
Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].
Cancer treatment reviews Pub Date : 2024-12-21 DOI: 10.1016/j.ctrv.2024.102866
Eugenia Cella, Alberto Bosio, Pasquale Persico, Mario Caccese, Marta Padovan, Agnese Losurdo, Marta Maccari, Giulia Cerretti, Tamara Ius, Giuseppe Minniti, Ahmed Idbaih, Nader Sanai, Michael Weller, Matthias Preusser, Matteo Simonelli, Giuseppe Lombardi
{"title":"Corrigendum to \"PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives\" [Cancer Treat. Rev. 131 (2024) 102850].","authors":"Eugenia Cella, Alberto Bosio, Pasquale Persico, Mario Caccese, Marta Padovan, Agnese Losurdo, Marta Maccari, Giulia Cerretti, Tamara Ius, Giuseppe Minniti, Ahmed Idbaih, Nader Sanai, Michael Weller, Matthias Preusser, Matteo Simonelli, Giuseppe Lombardi","doi":"10.1016/j.ctrv.2024.102866","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102866","url":null,"abstract":"","PeriodicalId":93922,"journal":{"name":"Cancer treatment reviews","volume":" ","pages":"102866"},"PeriodicalIF":0.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. 头颈部鳞状细胞癌的免疫疗法与表皮生长因子受体抑制剂联合疗法的现状与前景。
Cancer treatment reviews Pub Date : 2024-12-03 DOI: 10.1016/j.ctrv.2024.102864
Xin Tian, Hongyan Zhang, Yiman Han, Baoru Gu, Zhenyong Zhang
{"title":"Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma.","authors":"Xin Tian, Hongyan Zhang, Yiman Han, Baoru Gu, Zhenyong Zhang","doi":"10.1016/j.ctrv.2024.102864","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102864","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis, and the majority of patients with HNSCC are diagnosed at later stages owing to its hidden anatomical location and atypical clinical symptoms. It is notably prone to recurrence and metastasis. The traditional treatments include surgery, radiotherapy, chemotherapy, and targeted therapy. Although multiple treatment strategies have been established, the prognosis remains poor because most patients develop resistance to traditional treatments. In recent years, epidermal growth factor receptor (EGFR) inhibitors and immune checkpoint inhibitors (ICIs) have been shown to provide clinical benefits to these patients. Based on the promising results of both anti-EGFR therapy and immunotherapy, as well as the biological rationale for combining immunotherapy with anti-EGFR drugs, numerous preclinical and ongoing or completed clinical trials have explored the use of their synergistic effects. This review summarizes the feasibility of combining immunotherapy with EGFR inhibitors for HNSCC treatment and analyses the relevant biomarkers. It also summarizes the strategies for clinical applications. We found that immunotherapy and EGFR inhibitor combination therapy showed promise in treating patients with HNSCC and exhibited safety with acceptable adverse events. This review may provide valuable insights for the future development of treatments and formulation of therapeutic strategies for HNSCC, as well as useful information for the future design of clinical trials.</p>","PeriodicalId":93922,"journal":{"name":"Cancer treatment reviews","volume":"132 ","pages":"102864"},"PeriodicalIF":0.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.
Cancer treatment reviews Pub Date : 2024-11-19 DOI: 10.1016/j.ctrv.2024.102861
Chunfang Hao, Yunchu Wei, Wenjing Meng, Jie Zhang, Xiaonan Yang
{"title":"PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.","authors":"Chunfang Hao, Yunchu Wei, Wenjing Meng, Jie Zhang, Xiaonan Yang","doi":"10.1016/j.ctrv.2024.102861","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102861","url":null,"abstract":"<p><p>Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays a pivotal role in the development and progression of various cancers. In hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, aberrations in this pathway are increasingly recognized as key drivers of resistance to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, the first-line treatments for this disease subtype. Recognizing the urgent need for alternative therapeutic strategies, significant advancements have been made in developing PI3K/AKT/mTOR inhibitors for HR+ advanced/metastatic breast cancer. Among these inhibitors, capivasertib and alpelisib have received approval as targeted therapies for this indication. This review provides a comprehensive summary of the latest developments in PI3K/AKT/mTOR inhibitors for HR+ breast cancer. It also delves into different aspects, including sampling, testing method and timing, of PI3K/AKT/mTOR diagnostic testing. Additionally, the review discusses key considerations for integrating these inhibitors into clinical practice, such as timing and choice of PI3K/AKT/mTOR inhibitors, and management of treatment toxicities. By examining these different aspects, this review aims to provide valuable insights into optimizing the clinical utility of PI3K/AKT/mTOR inhibitors in HR+ advanced breast cancer.</p>","PeriodicalId":93922,"journal":{"name":"Cancer treatment reviews","volume":"132 ","pages":"102861"},"PeriodicalIF":0.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysis. 在分期和监测的背景下,早期直肠癌局部切除与根治术的肿瘤治疗效果:系统回顾和荟萃分析。
Cancer treatment reviews Pub Date : 2024-05-12 DOI: 10.1016/j.ctrv.2024.102753
Michael G Fadel, Mosab Ahmed, Annabel Shaw, Matyas Fehervari, Christos Kontovounisios, Gina Brown
{"title":"Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysis.","authors":"Michael G Fadel, Mosab Ahmed, Annabel Shaw, Matyas Fehervari, Christos Kontovounisios, Gina Brown","doi":"10.1016/j.ctrv.2024.102753","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102753","url":null,"abstract":"<p><strong>Background: </strong>Local resection (LR) methods for rectal cancer are generally considered in the palliative setting or for patients deemed a high anaesthetic risk. This systematic review and meta-analysis aimed to compare oncological outcomes of LR and radical resection (RR) for early rectal cancer in the context of staging and surveillance assessment.</p><p><strong>Methods: </strong>A literature search of MEDLINE, Embase and Emcare databases was performed for studies that reported data on clinical outcomes for both LR and RR for early rectal cancer from January 1995 to April 2023. Meta-analysis was performed using random-effect models and between-study heterogeneity was assessed. The quality of assessment was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias 2.0 tool for randomised controlled trials.</p><p><strong>Results: </strong>Twenty studies with 12,022 patients were included: 6,476 patients had LR and 5,546 patients underwent RR. RR led to an improvement in 5-year overall survival (OR 1.84; 95 % CI 1.54-2.20; p < 0.0001; I<sup>2</sup> 20 %) and local recurrence (OR 3.06; 95 % CI 2.02-4.64; p < 0.0001; I<sup>2</sup> 39 %) when compared to LR. However, when staging and surveillance methods were clearly adopted in LR cases, there was an improvement in R0 rates (96.7 % vs 85.6 %), 5-year disease-free survival (93.0 % vs 77.9 %) and overall survival (81.6 % vs 79.0 %) compared to when staging and surveillance was not reported/performed.</p><p><strong>Conclusions: </strong>LR may be appropriate for selected patients without poor prognostic factors in early rectal cancer. This study also highlights that there is currently no single standardised staging or surveillance approach being adopted in the management of early rectal cancer. A more specified and standardised preoperative staging for patient selection as well as clinical and image-based surveillance protocols is needed.</p>","PeriodicalId":93922,"journal":{"name":"Cancer treatment reviews","volume":"128 ","pages":"102753"},"PeriodicalIF":0.0,"publicationDate":"2024-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信